GS-5801
/ Gilead
- LARVOL DELTA
Home
Next
Prev
1 to 3
Of
3
Go to page
1
January 07, 2026
Panduratin A from Boesenbergia rotunda suppresses hepatitis B virus by targeting HNF1α and synergizing with antiviral agents.
(PubMed, Chin Med)
- "Panduratin A is a potent anti-HBV compound that acts primarily through HNF1α-dependent suppression of HBV transcription and replication. Its efficacy in combination therapy and in 3D liver models highlights its potential as a promising candidate for future HBV treatment strategies."
Journal • Hepatitis B • Infectious Disease • Inflammation
December 09, 2022
Characterization of a KDM5 small molecule inhibitor with antiviral activity against hepatitis B virus.
(PubMed, PLoS One)
- "Evaluation of GS-5801 antiviral activity in a humanized mouse model of HBV infection, however, did not result in antiviral efficacy, despite achieving pharmacodynamic levels of H3K4me3:H3 predicted to be efficacious from the in vitro model. Here we discuss potential reasons for the disconnect between in vitro and in vivo efficacy, which highlight the translational difficulties of epigenetic targets for viral diseases."
Journal • Hepatitis B • Hepatology • Infectious Disease • Inflammation
March 18, 2019
The pleiotropic association between IL-10 levels and CVD prognosis: Evidence from a meta-analysis.
(PubMed, Cytokine)
- "Data from the GSE58015 dataset were used to investigate the levels of IL-10 under certain conditions...Furthermore, our data mining analysis supported our findings. Our analysis showed that IL-10 levels may be pleiotropically associated with the CVD prognosis possibly based on the type of pathology, disease stage and levels of other proinflammatory factors, such as IL-6."
Journal • Retrospective data • Cardiovascular
1 to 3
Of
3
Go to page
1